HEALTH-SOVEREIGNTY & MEDTECH DESK · DISPATCH
On 5 June 2025, the African Export-Import Bank (Afreximbank) signed a US$75 million financing term sheet with Nigeria's government-owned Bank of Industry (BOI) — a facility designed to be on-lent to local small and medium-sized manufacturers under Nigeria's Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC). A term sheet is the stage before a facility: terms agreed, capital not yet flowing. That staging matters, and so does what the facility names. The eligible categories, as reported, run explicitly to medical diagnostic equipment, healthcare consumables, medical technology, and devices, alongside pharmaceuticals — a financing instrument that writes the device-and-diagnostics layer into its terms rather than leaving it implied under "healthcare."
The architecture is the analytical point. This is not a multilateral picking winners among Nigerian device makers; it is a two-layer structure in which the continental institution wholesales credit to the national development bank, and the national bank retails it to the manufacturers. Each layer does what only it can do: Afreximbank brings hard-currency scale no single Nigerian SME could access, while the BOI brings the local underwriting knowledge no continental balance sheet possesses. The sovereign thread runs through both — a state-owned lender executing a presidential initiative with multilateral capital behind it.
The policy wrapper is named, which is itself information. PVAC is Nigeria's stated program for building a domestic healthcare value chain, and this facility gives that program a credit instrument rather than a procurement one — capacity financed into existence, not imports substituted by decree. The signing's setting reinforced the direction of travel: it came, as reported, alongside the commissioning of Afreximbank's US$300 million African Medical Centre of Excellence in Abuja — an institution-building project of a different object type than the term sheet, and not additive to it.
The honest caveats travel with the piece. The event is sourced to Nigerian financial press reporting rather than an institutional release, and the record does not show a subsequent financial close for the facility — between a signed term sheet and disbursed naira sits the full distance of documentation, drawdown conditions, and the on-lending pipeline itself. Sub-Saharan Africa's device dependency was the pandemic's bluntest lesson; a US$75 million wholesale line is a modest instrument against it.
But the desk has watched this pattern before — Morocco's Promamec, Senegal's dialysis-kit line, Kenya's oxygen plants — and the pattern is the point: development-finance institutions, one mid-sized facility at a time, building the manufacturing layer that stockpile diplomacy never reaches. Sovereignty over the supply chain is not declared at the summit; it is underwritten at the term sheet.
— Capital Statecraft Intelligence · Health-Sovereignty & MedTech Desk
Primary source(s): Nairametrics, 5 June 2025